LAUSR

1. Simone JV, Cornet JA, Abildgaard CF. Acquired von Willebrand’s syn‐ drome in systemic lupus erythematosus. Blood. 1968;31(6):806‐812. 2. Federici AB, RandJH, et al. Acquired von Willebrand syn‐ drome: data from an international registry. Thromb Haemost. 2000;84(2):345‐349. 3. Collins P, Budde U, Rand JH, Federici AB, Kessler CM. Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemoph Off J World Fed Hemoph. 2008;14(Suppl 3):49‐55. 4. Mital A, “Acquired von Willebrand Syndrome”. Adv Clin Exp Med Off. Organ Wroclaw Med Univ. 2016;25(6):1337‐1344. 5. Macik BG, Gabriel DA, White GC, High K, Roberts H. The use of high‐dose intravenous gamma‐globulin in acquired von Willebrand syndrome. Arch Pathol Lab Med. 1988;112(2):143‐146. 6. Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in pa‐ tients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood. 1998;92(8):2707‐2711. 7. Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the ac‐ quired von Willebrand syndrome. Blood. 2011;117(25):6777‐6785. 8. Federici AB. Use of intravenous immunoglobulin in pa‐ tients with acquired von Willebrand syndrome. Hum Immunol. 2005;66(4):422‐430.